Please assess the completion status of the following clinical trial:

Trial Title: Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis After Laparoscopic Surgery for Colorectal Cancer.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Objective diagnosis of colorectal cancer;~* Elective laparoscopic surgery for colorectal cancer~* Whatever the stage of cancer~* Antithrombotic prophylaxis with LMWH administered for 7±2 days after surgery~Exclusion Criteria:~* Age \< 18 years~* Surgery for non-cancer disease~* Duration of surgery \< 45 min~* Conversion to open surgery~* Other indication for anticoagulant therapy~* Known cerebral metastases~* Kidney or liver failure~* Known hemorrhagic diathesis or high risk for bleeding~* History of intracerebral bleeding or neurosurgery within 6 months~* History of heparin induced thrombocytopenia~* Pregnancy or lactation~* Refusal of informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rivaroxaban (Type: EXPERIMENTAL): Orally administered, at the dose of 10 mg OD for 3 weeks (extended prophylaxis)
- Placebo (Type: PLACEBO_COMPARATOR): Orally administered, OD for 3 weeks (extended prophylaxis)

Based on this trial design, predict the completion outcome and termination type (if applicable).